Charcot-Marie-Tooth Disease Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)
Condition: CMT Intervention: Biological: Engensis (VM202) Sponsor: Helixmith Co., Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 4, 2022 Category: Research Source Type: clinical trials
